Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Top Stories > The Silent Enemy: Insulin Resistance

The Silent Enemy: Insulin Resistance

Published by Gbaf News

Posted on April 18, 2018

3 min read

Last updated: January 21, 2026

UK's FTSE 100 and financial markets react to Russia's embassy statement on G7 loans to Ukraine - Global Banking & Finance Review — The image illustrates the UK's FTSE 100 index performance amid the controversy over G7 loans to Ukraine backed by frozen Russian assets. This reflects the ongoing financial tension and geopolitical implications discussed in the article.

The MealPlanner, the MedTech company creating solutions in the fight against diet related diseases has begun the development of their new App, MIRA Health-My Insulin Resistance App with the support of an EU-PERMIDES grant & collaboration with the National Netherlands Insurance within the Sparklab program.

Insulin Resistance (IR) is undiagnosed in 90% of the population that suffers from this precursor to serious, life-changing, diet centered disease. IR is the precursor of such health problems as polycystic ovary syndrome (PCOS), infertility, heart disease and diabetes, all of which have reached epidemic proportions, globally.

The MealPlanner combats insulin resistance in three ways:

Create awareness about IR. Even medical professionals confuse IR with pre-diabetes so public education is important for everyone. The outcome of this education is to get people to diagnose and test for IR from time to time just as we do with breast and prostate cancers.
With the PERMIDES grant we are creating a self-diagnostic tool to make preliminary diagnoses easy and free for all.
Our App supports the efforts of people to manage their IR with proper nutrition. The only way to prevent the onset of more serious disease is to learn healthy and mindful nutrition.

In addition to the EU grant the project has received its first 100k seed investment.

The Mealplanner is seeking further public participation in their efforts to educate the public about diet based disease and give them the tools needed to fight for healthy solutions. To learn more about the company and see further investment possibility click here.

The MealPlanner, the MedTech company creating solutions in the fight against diet related diseases has begun the development of their new App, MIRA Health-My Insulin Resistance App with the support of an EU-PERMIDES grant & collaboration with the National Netherlands Insurance within the Sparklab program.

Insulin Resistance (IR) is undiagnosed in 90% of the population that suffers from this precursor to serious, life-changing, diet centered disease. IR is the precursor of such health problems as polycystic ovary syndrome (PCOS), infertility, heart disease and diabetes, all of which have reached epidemic proportions, globally.

The MealPlanner combats insulin resistance in three ways:

Create awareness about IR. Even medical professionals confuse IR with pre-diabetes so public education is important for everyone. The outcome of this education is to get people to diagnose and test for IR from time to time just as we do with breast and prostate cancers.
With the PERMIDES grant we are creating a self-diagnostic tool to make preliminary diagnoses easy and free for all.
Our App supports the efforts of people to manage their IR with proper nutrition. The only way to prevent the onset of more serious disease is to learn healthy and mindful nutrition.

In addition to the EU grant the project has received its first 100k seed investment.

The Mealplanner is seeking further public participation in their efforts to educate the public about diet based disease and give them the tools needed to fight for healthy solutions. To learn more about the company and see further investment possibility click here.